Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Coherent Bio Closes B Round with $100 Million for XDC Candidates

publication date: May 17, 2023

Suzhou Coherent Biopharma closed a Series B+ round that brought its B/B+ funding to $100 million, which will be used for clinical trials of the company’s two lead candidates. Coherent develops drugs from its three XDC platforms – the “X” standing for all forms of drug conjugates, including ADC and PDC. Coherent will use the proceeds for clinical development of its bi-targeting XDC drug pipeline, which is aimed at treating breast cancer, solid tumors and prostate cancer. The Series B+ round was led by HM Capital. Shengdi Investment, a subsidiary of Hengrui Pharma, led the $75 million Series B round, completed last year. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital